(June 8, 2022) | By Paul Schloesser.

Two years after securing seed funding and remaining in a state of “semi-stealth,” a San Francisco biotech keen on combining evolution and small molecule discovery recently bagged a VC round that will let it do just that.

Known as Anagenex, the company announced Wednesday that it raised a $30 million Series A round, securing the attention of Catalio Capital Management as lead investor. A few other investors tagged along, such as Lux Capital and Khosla Ventures.